Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-SPY 2 Trial in Breast Cancer
NCT01042379Phase 2Recruiting
- Sponsor
- Quantum Leap Healthcare Collaborative
- Start
- Mar 2010
- Primary completion
- Dec 2030
- Modality
- Small Interfering RNA (siRNA), Irreversible Covalent Inhibitors, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of trebananib, ganitumab, MK-2206, trastuzumab emtansine, pertuzumab in breast cancer, sponsored by Quantum Leap Healthcare Collaborative. Started Mar 2010; status: recruiting.
02
Drugs
trebananibganitumabMK-2206trastuzumab emtansinepertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01042379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01042379.